 Nkarta Inc NASDAQ: NKTX has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data from the engineered CAR NK cell therapy candidate targeting the NKG2D ligand is expected in 1H of 2022, against the end of 2021 expected earlier. 